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Background: Lowering blood pressure (BP) leads to reduced risk of stroke,
myocardial infarction, and cardiovascular mortality. Single-pill combination therapies may
deliver better BP control than increasing the dose of monotherapies or using more
drugs separately.
Objectives: The aim of the present observational study was to investigate the real-life
use and the effect of first line or replacement single-pill combination therapies containing
irbesartan and hydrochlorothiazide (HCTZ) on systolic BP (SBP) control rate in patients
with hypertension.
Methods: Overall, 780 patients with moderate or severe hypertension either untreated
(289; 37%) or uncontrolled (491; 63%) with previous therapy were included in the
“First Line CombinAtion Therapy in the Treatment of Stage II and III Hypertension”
(FLASH) prospective Swiss national-wide cohort study. All recruited patients received
single-pill antihypertensive combination therapy containing HCTZ and irbesartan. BP was
measured at baseline and after 8-weeks follow-up according to guidelines.
Results: Mean reductions in office systolic/diastolic BP (SBP/DBP) were
23.7 ± 13.7/11.7 ± 8.5 mmHg, with reductions of 26.9 ± 14.1/13.0 ± 8.8 mmHg or
21.8 ± 13.1/11.0 ± 8.3 mmHg when the single-pill combination of irbesartan/HCTZ
was given as first line or replacement treatment, respectively (p < 0.001 for differences
between first line and replacement treatment in both SBP and DBP). The guidelines-
recommended goals were reached in 368 (47%), 492 (63%), and 312 (40%) patients
for SBP, DBP, and SBP/DBP, respectively. The SBP control rate was higher when the
combination was used as first line treatment (52 vs. 44%; p = 0.043). Overall, 145
adverse events were recorded; hypotension in 12 (1.5%) cases, hypokalaemia in 9
(1.2%), and hyperkalaemia in 3 (0.4%).
Conclusions: The single-pill combination of irbesartan/HCTZ was well-tolerated and
achieved substantial reductions in both systolic and diastolic BP. The SBP control rate
was greater when the combination was prescribed as first line treatment as suggested
by recent ESC/ESH guidelines.
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INTRODUCTION
Cardiovascular disease is the most common cause of death in
the population, and hypertension is one of the most important
treatable risk factors (1). Lowering blood pressure (BP) is
associated with considerable benefits including a reduced risk of
stroke, myocardial infarction, and cardiovascular mortality (2).
However, treating hypertension to targets is often challenging.
Data from clinical studies and registries suggest that more than
two-thirds of patients with hypertension require treatment with
two or more antihypertensive drugs to achieve their target BP
goals (3). It was shown that using a combination therapy lead
to a better BP control than increasing the dose of monotherapy
(4–7). Moreover, the concomitant use of drugs with different
mechanisms of action can offset potential side effects of each
drug (8). Taking these data into consideration, various single-pill
combinations have been developed and used to improve BP goals
attainment and patient adherence.
The combination of an angiotensin receptor blocker (ARB)
and hydrochlorothiazide (HCTZ) is well-tolerated and able
to effectively reduce BP, particularly when used as a single-
pill combination. Initial treatment with the ARB irbesartan
in combination with HCTZ has been proven to be as safe
as monotherapy and more effective in patients with moderate
and severe hypertension, in obese patients with mild-to-
moderate hypertension, and in patients with type 2 diabetes and
hypertension (9–14).
Swiss hypertension guidelines valid at the time when
the present study was conducted recommended the use
of combination therapies in all patients presenting with
systolic/diastolic BP above 160/100 mmHg, even if no treatment
was administered previously (15, 16). Nonetheless, hypertension
remains undertreated and there is a need to implement consensus
guideline recommendations in clinical practice (17). Many
physicians are reluctant to treat hypertension aggressively and
still prescribe low dose monotherapies for initial treatment. One
reason for this cautious approach is the fear of possible adverse
events, including hypotension.
In the present study, we aimed to investigate the patterns of
real-life use and the effect of first line or replacement combination
therapy containing HCTZ and irbesartan in terms of efficacy
and safety in patients with moderate or severe (stage II or
III) hypertension.
MATERIALS AND METHODS
Study Population
In the “First Line CombinAtion Therapy in the Treatment of
Stage II and III Hypertension” (FLASH) prospective national
cohort study, private-practice based cardiologists and general
practitioners across all regions of Switzerland were invited
to enroll up to six patients per physician during a 1-year
period between September 2008 and 2009. For the purpose of
representativeness, Switzerland was divided into 10 geographic
sectors of similar territorial and population size, and for each
of these sectors, 14 physicians were randomly selected from a
centralized national register and asked to participate in this study.
Inclusion criteria were age ≥18 years, moderate or severe (stage
II or III) hypertension either untreated or uncontrolled with
previous antihypertensive therapy. All patients received single-
pill antihypertensive combination therapy containing HCTZ and
irbesartan; those previously untreated as first line and those
previously uncontrolled as replacement treatment. There were no
exclusion criteria. Written informed consent was obtained.
The study period included 8 weeks follow-up after the baseline
visit. The primary endpoint was the guidelines-recommended
systolic BP goal attainment of below 140 mmHg after 8 weeks
of antihypertensive combination therapy.
The study was approved by the ethics committee in
accordance with local regulations valid at the time of
study conduct.
Data and Definitions
Data were collected by treating physicians and entered in a
standardized case report form. At the baseline visit, following
parameters were recorded: patient characteristics including
age, gender, weight, height, cardiovascular risk factors and
co-morbidities, previous antihypertensive treatment and co-
medication (if any), office systolic and diastolic BP [seated,
mean of two consecutive measurements by automatic devices
spaced by 1–2min, according to guidelines (15, 18)] prior to the
initiation of combination therapy containing HCTZ, and new
antihypertensive combination treatment. Individual BP goals
were determined according to former Swiss guidelines (<130/80
mmHg for diabetic patients and those with renal disease, and
<140/90 mmHg for non-diabetic patients and those without
renal disease). At the follow-up visit, office systolic and diastolic
BP (seated) control, treatment tolerability including occurrence
of hypotension, and compliance with study medication were
recorded, and in patients not at goal a change in antihypertensive
therapy was suggested.
In patients without diabetes mellitus, BP was categorized as
normal (systolic 120–129 mmHg and or diastolic 80–84 mmHg),
high normal (systolic 130–139 mmHg and or diastolic 85–89
mmHg), mild (stage I) hypertension (systolic 140–159 mmHg
and or diastolic 90–99 mmHg), moderate (stage II) hypertension
(systolic 160–179 mmHg and or diastolic 100–109 mmHg),
and severe (stage III) hypertension (systolic ≥180 mmHg and
or diastolic ≥110 mmHg) (15, 18). The real threshold for
hypertension should have been considered as flexible and based
on the total cardiovascular risk profile of each individual (18).
Clinically confirmed cardiovascular diseases were defined
as myocardial infarction or coronary heart disease, heart
failure, atrial fibrillation, stroke or transient ischemic attack,
peripheral artery disease, and chronic kidney disease. Additional
cardiovascular risk factors were defined as type I and type II
diabetes mellitus, dyslipidaemia, smoking, overweight or obesity,
and physical inactivity. Hypokalaemia was defined as serum
potassium <3.5 mmol/l and hyperkalaemia as serum potassium
>5.0 mmol/l.
First line therapy was defined as the administration of BP-
lowering medication in patients with untreated hypertension at
the baseline visit and replacement therapy as the use of BP-
lowering medication in patients with uncontrolled hypertension
at baseline despite previous antihypertensive treatment.
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Statistical Analysis
Based on the results of previous studies, we assumed that 60%
of patients would attain the guidelines-recommended BP targets
after 8 weeks of treatment with antihypertensive combination
therapy. To reach a precision of ±5.0% of the 95% confidence
interval (CI) for the estimated proportion of patients at goal,
a minimum sample of 369 patients per group (first line and
replacement combination therapy) was calculated.
Continuous variables with a normal distribution are presented
as means with standard deviations (SD), and group comparisons
were performed with the t-test; continuous variables with skewed
distribution are described as median values with interquartile
ranges (IQR), and group comparisons were performed using a
rank-sum test. Discrete variables are depicted as frequencies and
percentages, and group comparisons were performed with the chi
square or Fisher’s exact test. Data were analyzed using the STATA
10 software (STATACorp LP, College Station, Texas, USA).
RESULTS
Patient Characteristics
Overall, 780 patients were enrolled by 135 participating
physicians. Their mean age was 61± 12 (range 27–92) years, 342
(44%) patients were female, mean weight was 81 ± 16 kg, and
mean height 169± 9 cm.
At baseline, 491 (63%) patients had uncontrolled hypertension
despite prior BP-lowering therapy; of those, 158 (32%) were
previously treated with an ARB, 135 (27%) with angiotensin
converting enzyme-inhibitors (ACE-I), 141 (29%) with beta-
blockers (BB), 89 (18%) with calcium channel-blockers (CCB),
and 72 (15%) with diuretics other than HCTZ; thus, 104 (21%)
patients received prior combination therapy.
Patients with uncontrolled hypertension despite previous
therapy were older than those with untreated hypertension at
baseline (64 ± 11 vs. 56 ± 11 years; p < 0.001), had more
often clinically confirmed cardiovascular disease, and had more
additional cardiovascular risk factors (Table 1).
At baseline, mean office systolic BP of the entire group was
161 ± 13 mmHg and the mean diastolic BP was 95 ± 8 mmHg.
In comparison to patients with uncontrolled hypertension, those
with untreated hypertension had a higher baseline systolic (163
± 12 vs. 159 ± 13 mmHg; p < 0.001) and diastolic (97 ± 8 vs.
93 ± 9 mmHg; p < 0.001) BP. Based on the guidance by treating
physicians, mean individual BP goals were set at 136 ± 6 mmHg
for systolic BP and 84± 5 mmHg for diastolic BP.
BP Treatment
Among the 289 patients with untreated hypertension at baseline,
187 (65%) were prescribed irbesartan 150mg plus 12.5mg
HCTZ, 75 (26%) irbesartan 300mg plus 12.5mg HCTZ, and 27
(9%) irbesartan 300mg plus 25mg HCTZ as first line therapy.
Among the 491 patients with uncontrolled hypertension at
baseline, 181 (37%) were prescribed irbesartan 150mg plus
12.5mg HCTZ, 176 (36%) irbesartan 300mg plus 12.5mg
HCTZ, and 134 (27%) irbesartan 300mg plus 25mg HCTZ as
replacement therapy (p < 0.001 for untreated vs. uncontrolled
hypertension at baseline).
TABLE 1 | Clinically confirmed cardiovascular disease and additional
cardiovascular risk factors in patients with uncontrolled hypertension despite
previous therapy and in those with untreated hypertension at baseline.
Uncontrolled
N = 491
Untreated
N = 289
Total
N = 780
P
Established cardiovascular
disease, n (%)*
206 (42.0) 38 13.1 244 31.3 <0.001
Coronary heart disease, n (%) 72 (14.7) 7 2.4 79 10.1 <0.001
Peripheral artery disease, n (%) 36 (7.3) 5 1.7 41 5.3 0.001
Heart failure, n (%) 37 (7.5) 0 0.0 37 4.7 <0.001
Atrial fibrillation, n (%) 36 (7.3) 1 0.3 37 4.7 <0.001
Chronic kidney disease, n (%) 28 (5.7) 3 1.0 31 4.0 0.001
Stroke or transient ischemic
attack, n (%)
27 (5.5) 2 0.7 29 3.7 0.001
Additional cardiovascular
risk factors, n (%)**
437 (89.0) 239 82.7 676 86.7 0.012
Physical inactivity, n (%) 240 (48.9) 140 48.4 380 48.7 0.91
Dyslipidemia, n (%) 261 (53.2) 92 31.8 353 45.3 <0.001
Overweight or obesity, n (%) 162 (33.0) 88 30.4 250 32.1 0.46
Smoking, n (%) 125 (25.5) 103 35.6 228 29.2 0.003
Diabetes mellitus type II, n (%) 146 (29.7) 40 13.8 186 23.8 <0.001
Diabetes mellitus type I, n (%) 13 (2.6) 3 1.0 16 2.1 0.13
Bold identified total cardiovascular diseases and total cardiovascular risk factors, the single
diseases and factors are listed.
*some patients had more than one cardiovascular disease.
**some patients had more than one additional cardiovascular risk factor.
Prescription of increasing dose of irbesartan plus HCTZ was
associated with increasing age (p = 0.001) and body weight (p <
0.001) but not with systolic and diastolic BP at baseline.
BP Reduction, Goal Attainment, and
Tolerability
At the follow-up visit, mean systolic BP was 137 ± 11 mmHg
and mean diastolic BP was 83 ± 8 mmHg. Mean reductions in
systolic/diastolic BP after 8 weeks were 23.7 ± 13.7/11.7 ± 8.5
mmHg vs. baseline, with a reduction of 26.9 ± 14.1/13.0 ± 8.8
mmHg or 21.8 ± 13.1/11.0 ± 8.3 mmHg when the single-pill
combination was given as first line or replacement treatment,
respectively (p < 0.001 for difference between first line and
replacement treatment in both systolic and diastolic BP). The
development of the mean average BP is displayed in Figure 1.
In total, the guidelines-recommended goals for systolic BP
were reached in 368 (47%; 95% CI 44–51%) patients, for diastolic
BP in 492 (63%; 95% CI 60–66%), and for both systolic and
diastolic BP in 312 (40%; 95% CI 37–43%). There was a higher
goal attainment in systolic BP when the single-pill combination
of irbesartan and HCTZ was chosen as first line vs. replacement
treatment (52 vs. 44%; p = 0.043) (Table 2). The rate of goal
attainment in diastolic BP was similar when the single-pill
combination of irbesartan and HCTZ was chosen as first line vs.
replacement treatment (66 vs. 62%; p = 0.24), and the same was
true for goal attainment in both systolic and diastolic BP (43 vs.
38%; p= 0.20).
During the study period, 145 adverse events were recorded.
Of those, 82 (57%) cases were classified as headache, 62 (43%)
dizziness, 12 (8%) hypotension, 9 (6%) hypokalaemia, and 3 (2%)
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FIGURE 1 | Average systolic and diastolic BP at baseline and follow-up visit. BP, Blood Pressure; HCTZ, Hydrochlorothiazide.
TABLE 2 | BP goal attainment in first line and replacement single-pill combination
therapy containing HCTZ.
Replacement
therapy
N = 491
First line
therapy
N = 289
Total
N = 780
P
Systolic BP goal
attainment, n (%)
218 (44.4) 150 51.9 368 47.2 0.043
Diastolic BP goal
attainment, n (%)
302 (61.5) 190 65.7 492 63.1 0.24
Both systolic and
diastolic BP goal
attainment, n (%)
188 (38.3) 124 42.9 312 40.0 0.20
BP, Blood Pressure; HCTZ, Hydrochlorothiazide.
hyperkalaemia. Some patients had more than one adverse event.
There was no difference in the occurrence of adverse events when
the single-pill combination of irbesartan and HCTZ was chosen
as first line or replacement treatment, besides a lower incidence
of headache (8 vs. 12%; p= 0.043) (Table 3). Overall, compliance
with study medication was rated as 100% in 368 (47%) patients,
80% in 286 (37%), 50–80% in 69 (9%), and 50% in 13 (2%), and
was not reported in 44 (5%).
DISCUSSION
Irbesartan/HCTZ combination therapy used as both first
line and replacement treatment were highly effective in
lowering BP in patients with stage II and III hypertension.
The response to treatment was rapid and interestingly, a
larger reduction in BP was reached in previously untreated
patients compared to patients who had responded inadequately
to prior antihypertensive treatment, confirming the current
recommendation of rather aggressive combination therapy as
the preferred option for initial treatment of stage II or III
hypertension (4, 5, 7, 16). However, even in patients previously
treated the extent of BP lowering was substantial, suggesting
perhaps some adherence issue to prior therapy. As a result of
the efficient reduction in BP and good tolerability, many more
patients may be able to reach the suggested BP targets when
treated with the single-pill combination of irbesartan/HCTZ. The
treatment of hypertension should be performed with the aim of
attaining BP goals relatively rapidly, since significant delays or
TABLE 3 | Adverse events in first line and replacement single-pill combination
therapy containing HCTZ.
Replacement
therapy
N = 491
First line
therapy
N = 289
Total
N = 780
P
Any adverse event, n (%)* 99 (20.2) 46 15.9 145 18.6 0.14
Headache, n (%) 60 (12.2) 22 7.6 82 10.5 0.043
Dizziness, n (%) 37 (7.5) 25 8.7 62 7.9 0.58
Hypotension, n (%) 8 (1.6) 4 1.4 12 1.5 0.79
Hypokalaemia, n (%) 7 (1.4) 2 0.7 9 1.2 0.35
Hyperkalaemia, n (%) 2 (0.4) 1 0.3 3 0.4 0.89
HCTZ, Hydrochlorothiazide. Bold identified total cardiovascular diseases and total
cardiovascular risk factors, the single diseases and factors are listed.
*some patients had more than one adverse event.
failure to achieve goals are associated with an increased risk of
cardiovascular events in high risk patients (19). Since patients
with moderate or severe hypertension are likely to require two or
more agents to reach BP goals, the current recommendations of
the Swiss, European, and American Societies of Hypertension are
to initiate therapy with a single-pill combination in these patients
(15, 18, 20).
The FLASH study involving 780 patients investigated the
efficacy and safety of a single-pill combination BP-lowering
therapy including HCTZ and irbesartan in subjects with
moderate or severe hypertension, one third previously untreated
and two thirds in whom prior therapy had not been sufficient to
reach the target BP. The clinical profile of the study participants
was balanced and in line with the patient characteristics from the
CoLaus study, and it may thus be considered representative of the
Swiss population of patients with hypertension (21, 22).
Not surprisingly, patients with uncontrolled hypertension
despite prior antihypertensive therapy had a lower BP at baseline
than previously untreated patients, were older and characterized
by a higher proportion of clinically confirmed cardiovascular
disease and additional cardiovascular risk factors (except of
smoking). In such a population, adherence to medication is often
an issue and the use of fixed-dose drug combination therapies is
particularly helpful to reduce the pill burden (23).
Safety and tolerability, including hypotension, syncope,
headache, and hypokalaemia are often used as an argument
against aggressive antihypertensive therapy. In the present study,
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the single-pill combinations of irbesartan/HCTZ were well-
tolerated (15, 16, 18, 20). Some treatment-related effects, such
as hypotension and change in kalaemia with irbesartan/HCTZ
combination therapy were observed, but none of these side
effects was described as severe and there was no excess of
withdrawals due to these side effects. Headache was frequent in
our study. In the absence of a placebo group, it is difficult to judge
how often headache was due to the combination of irbesartan
and hydrochlorothiazide. In previous surveys, the incidence of
headache was lower with angiotensin receptor antagonists than
with placebo (24). A review published in 2001 reported a 30%
incidence of side effects with different ARBs (25). As such, the
incidence of side effect found in our study is less than reported in
the literature, confirming that irbesartan and the combination of
irbesartan and HCTZ are well-tolerated.
These findings are re-assuring and confirm the approach of
the Swiss, European, and American Society of Hypertension in
recommending aggressive two-drug therapy as initial treatment
for patients with moderate or severe hypertension, and
suggesting that this strategy can be pursued in a real-life setting
without compromising patient safety (15, 16, 18, 20).
Our results are also consistent with other studies evaluating
the effect of the fixed-dose combination of irbesartan/HCTZ
(12). The benefits and good tolerability of irbesartan/HCTZ
combination therapies have been demonstrated in a number of
trials in patients with mild hypertension who failed to achieve BP
control with monotherapy, as well as in patients with moderate
or severe hypertension, renal failure, and in hypertensive type II
diabetics with early or late-stage diabetic nephropathy (10, 26–
28). Tolerability and the use of fixed-dose drug combinations are
important factors impacting on patient’s adherence and therefore
on achievement of BP targets (23).
The present study has several limitations: First, the study
was observational and the follow-up was limited to a short-
term period. Second, the choice of antihypertensive therapy
was not determined by an experimental plan but solely
as the result of the treatment decision by the physician
in charge. Third, we cannot exclude considerable inclusion
bias because participating physicians had to enroll up to 6
patients only and may have selected those who were likely
to respond best although many of them were uncontrolled.
Due to lack of randomization and lack of a placebo arm
in our study the results are to be considered hypothesis
generating, not confirmatory, and therefore must be interpreted
with caution. In contrast to randomized controlled trials, our
study had no exclusion criteria and the results reflect the
contemporary clinical practice. Finally, the study was performed
in Switzerland only and the results may not be applicable to
other regions.
In conclusion, the FLASH study suggests that
irbesartan/HCTZ combination therapy is effective and
well-tolerated in a population of patients with moderate
or severe (stage II or III) hypertension either untreated
or uncontrolled with previous therapy. The use of the
single-pill combination of irbesartan/HCTZ as first line or
replacement treatment achieved substantial reductions in both
systolic and diastolic BP, with greater BP reductions when the
combination therapy was chosen as first line vs. replacement
treatment. The therapy was well-tolerated, and nearly half of
the patients reached the guidelines-recommended BP target
of <140/90 mmHg.
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